Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company reported $5.07 million in revenue, down 7.7% sequentially and down 63.6% year over year. The company had a negative gross profit margin of 152.5% on a negative gross profit of $8 million, which has ballooned from a negative $0.68 million in the first quarter.

MediPharm Labs has 5 analysts covering their name, with an average 12-month price target of $0.60, or a 74% upside. The average is lower than the $0.73 average from last month due to two analysts lowering their price targets after the quarterly results. Out of the 5 analysts, 1 has a strong buy rating, 2 have buys and the other 2 have hold ratings. The street high sits at $0.80 and the lowest comes in at $0.40.

Canaccord Genuity was one of the firms to lower its 12-month price target. They now have a $0.70 price target, down from $0.75, while reiterating their speculative buy rating. They add that the company’s international sales overshadow headwinds on domestic operations.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

For the quarter, MediPharm Labs basically missed on every estimate other than adjusted EBITDA, which was -$3.675 million compared to the -$4 million estimate. For the segments, MediPharm saw its Canadian adult-use segment lose market share again, as revenue came in at $2.6 million, compared to the $3.4 million in the first quarter.

Canaccord says they are not too surprised by the revenue drop in domestic markets due to the company pivoting to health & wellness offerings which are better suited for international sales than domestic. International sales grew 17% sequentially to $2.5 million due to better sales in Germany. They add, “we believe that H2/21 will see material uplifts in the company’s international cannabis contributions.”

Canaccord also touches on the companies July 14 news release, in which MediPharm received a Drug Establishment License, which allows it to “manufacture any nonsterile drug in finished good or active pharmaceutical ingredient API formats.” Canaccord is generally bullish on the company to be able to make this license accretive in the long term, while in the short term they expect the license to help expedite importation and exportation timelines for the international supply chain.

Below you can see Canaccord’s updated full year 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

K92 Mining: BMO Reiterates Ratings After 2022 Guidance Release

On January 24th, K92 Mining Inc. (TSX: KNT) announced their 2022 operational guidance, wherein the...

Sunday, January 30, 2022, 01:12:00 PM

Lundin Mining: BMO Lowers Target After Weaker Than Expected Guidance

On November 22nd, Lundin Mining Corporation (TSX: LUN) provided production guidance all the way out...

Wednesday, November 24, 2021, 04:18:00 PM

Galaxy Digital Sees BMO Slash Price Target From $35 To $24

Galaxy Digital (TSX: GLXY) reported its first quarter financial results on Monday. The company said...

Thursday, May 12, 2022, 04:33:00 PM

US Cannabis: Stifel Expects Growth To Decelerate In Q4 Earnings

On February 2nd, Stifel-GMP put out their fourth quarter 2021 earnings preview, calling it “The...

Wednesday, February 9, 2022, 04:33:00 PM

Canaccord Genuity Downgrades Charlotte’s Web Price Target To C$7.75 From C$9

Yesterday, Charlotte’s Web Holdings (TSX: CWEB) reported their second-quarter 2020 financials. Consolidated revenue came in...

Tuesday, September 15, 2020, 11:33:48 AM